...
首页> 外文期刊>HIV therapy >Possible applications for replicating HIV 1 vectors.
【24h】

Possible applications for replicating HIV 1 vectors.

机译:复制HIV 1载体的可能应用。

获取原文
获取原文并翻译 | 示例
           

摘要

Since its discovery some 25 years ago, much has been learned about HIV type 1 and the molecular details of its replication cycle. This insight has been used to develop lentiviral vector systems that have advantages over conventional retroviral vector systems. For safety reasons, the lentiviral vector systems are replication incompetent and the risk of generating a replication competent virus has been minimized. Nevertheless, there may be certain applications for replication competent HIV based vector systems, and we will review our activities in this particular field. This includes the generation of a conditionally replicating HIV 1 variant as a safe live attenuated virus vaccine, the construction of mini HIV variants as cancer selective viruses for virotherapy against leukemia, and the use of a conditionally live anti HIV gene therapy vector. Although safety concerns will undoubtedly remain for the use of replication competent HIV based vector systems, some of the results in cell culture systems are very promising and warrant further testing in appropriate animal models.
机译:自大约25年前被发现以来,人们已经对1型HIV及其复制周期的分子细节有了很多了解。该见解已被用于开发慢病毒载体系统,该系统具有优于常规逆转录病毒载体系统的优势。出于安全原因,慢病毒载体系统不能复制,并且将产生复制型病毒的风险降到最低。然而,可能有一些具有复制能力的基于HIV的媒介系统的应用,我们将回顾我们在这一特定领域的活动。这包括产生有条件复制的HIV 1变异体作为安全的减毒活病毒疫苗,构建小型HIV变异体作为用于针对白血病的病毒疗法的癌症选择性病毒以及使用有条件的抗HIV基因治疗载体。尽管使用具有复制能力的基于HIV的载体系统无疑会带来安全隐患,但细胞培养系统中的某些结果非常有前途,需要在适当的动物模型中进行进一步测试。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号